Verition Fund Management LLC Sells 31,562 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

Verition Fund Management LLC trimmed its position in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 69.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,035 shares of the company’s stock after selling 31,562 shares during the quarter. Verition Fund Management LLC’s holdings in GoodRx were worth $97,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of GDRX. Cornercap Investment Counsel Inc. lifted its position in GoodRx by 1.7% during the second quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock valued at $587,000 after purchasing an additional 1,266 shares during the last quarter. nVerses Capital LLC purchased a new stake in shares of GoodRx during the 3rd quarter valued at $33,000. Plato Investment Management Ltd bought a new stake in shares of GoodRx during the 2nd quarter worth $43,000. XTX Topco Ltd grew its position in GoodRx by 42.4% in the second quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock worth $231,000 after acquiring an additional 8,801 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its position in GoodRx by 5.9% during the second quarter. Canada Pension Plan Investment Board now owns 166,142 shares of the company’s stock valued at $1,296,000 after purchasing an additional 9,200 shares in the last quarter. 63.77% of the stock is currently owned by institutional investors.

GoodRx Stock Performance

Shares of GDRX stock opened at $4.46 on Wednesday. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock has a fifty day moving average of $5.48 and a 200 day moving average of $7.04. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -148.67, a PEG ratio of 3.54 and a beta of 1.29. GoodRx Holdings, Inc. has a 52 week low of $4.09 and a 52 week high of $9.26.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Citigroup reduced their price objective on GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Barclays decreased their price target on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Morgan Stanley cut their price objective on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday. Finally, Mizuho began coverage on shares of GoodRx in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, GoodRx has a consensus rating of “Moderate Buy” and an average price target of $8.37.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.